FontsA A
ContrastA A
Newsletter sign-up
I give permission for BBMRI-ERIC to send me their newsletter and emails about subjects which they think may be of interest to me. I can unsubscribe from all emails at any time. I understand that my information will be processed according to BBMRI-ERIC's privacy notice.


cliniMARK: Good biomarker practice to increase the number of clinically validated biomarkers

Topic: H2020 OC-2016-1-20724

Type of Action: COST

Duration: 48 months

Start date: 14th March 2017

Grant agreement: CA16113


Total request Grant by Consortium:

Total request Grant by BBMRI-ERIC:

Assigned 3rd parties/BBMRI-ERIC Framework Agreement: none

Benefit/tasks for BBMRI-ERIC: Experts contributing to the establishment of best biomarker practices, networking

Status: approval date 24th October 2016

Chair: Theo M. Luider

Vice Chair: Antonia Vlahou



Thousands of circulating proteins have been shown to be hallmarks of emerging disease, response to treatment, or a patients’ prognosis. The identification of these small molecule biomarkers holds a great promise for significant improvement of personalized medicine based on simple blood tests. For instance, diagnosis and prognosis with biomarkers (e.g. carcinoembryonic antigen (CEA)) has significantly improved patient survival and decreased healthcare costs in colorectal cancer patients. Unfortunately, despite significant investments to increase the number of biomarker studies, only 150 out of thousands of identified biomarkers have currently been implemented in clinical practice. This is mainly caused by the timeconsuming process of reliably detecting biomarkers, the irreproducibility of studies that determine a biomarkers’ clinical value, and by a mismatch in studies that are performed by academia and what is required for regulatory and market approval. To increase the number of clinically validated biomarkers, rather than further increasing the number of biomarker discovery studies, CliniMARK will improve the quality and reproducibility of studies and establish a coherent biomarker development pipeline from discovery to market introduction.

CliniMARK aims to achieve said goal by creating a Best Biomarker Practice (BBP) community, which will provide guidance to:

  1. Classify biomarkers according to their characteristics, anticipated clinical use, and their phase of development,
  2. Select and validate appropriate research-grade biomarker detection tests,
  3. Select appropriately designed studies and biological samples to reliably and reproducibly validate biomarkers clinically, and
  4. Select and report on appropriate clinical data storage, biomarker data storage, data analysis protocols, privacy concerns, ethical issues, and statistical analysis methods.

The website was co-funded within ADOPT BBMRI-ERIC, a project that has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 676550.
We use cookies to analyse the traffic on our websites. All personal data is anonymized and not shared with third parties! Click here for more information.